Ann: Becoming a substantial holder, page-9

First 9 Last

Share
Profile

Follow
Cuprum29

2,117 Posts.

264

07/01/25

15:21

Post #: 77303755
Share

Originally posted by samfiodiving: ↑

Gassy how do you know this about PVL

Look on the other side of the coin are they aligned witgh this hostile move

after all we are nothing more than a mere shell at this moment in time with what $17mil in the bank

PVL back these guys in get a seat on the board and you should be able to work the rest out for yourself

If they are aligned with this then look at the last AGM vote take away Platinums vote 1oomil shares and it leaves this board very exposed

Please dont rant i just want you to look at the ugly side for one moment thats all

What i am dissapointed with is the info put to market yes i understand and accept that the drug failed

But if they had enough info to can the trial then with out a major drill down they should have enough info to put to market that our drug did or did not reduce our target being CD49d

If we have had no effect then IMHO one has to question why was this, was it the drug manufacture as we have always managed to reduce the numbers in our target in both the last trial and in MS infact it was the main reason we entered this DMD field because of the reuction of CD49d

If their is zero effect then one would have to go back to drug manufacture was it in fact made by the same people that manufactured our 2A drug

i have no idea

But if you cast you mind back to the my tomorrows early access for 1102 or 1103 i cannot remember which one it was exactly without checking as they were supposed to have done both EAP and neither actually eventuated

But on one of the occasions My tommorrows got the drug knocked back because the drug was not manufactured by the same people as the original manufacturer and that new dose they wanted to use would have had to go through the rigours of a clinical trial to be used

hence the EAP in Europe with my tomorows was dropped

I am not having a go here gassy just trying to put some perspective into this failure

if our target in CD49d shows no change then one would have to look at the drug manufacture and ask was it indeed the same manufacturer that made the drug for our trial in 2a which showed so much promise,

as can be seen from that previous EAP with my tomorows, drug manufacture would appear to be a super imperative part of the actual trial infact critical as we were knocked back for using omeone else

Was the ball dropped here i have no idea just looking for answers unlike you that appears to have just accepted it failed

If you go of on a rant i will not engage i havnt come here for that

I like you and many others have lost and will accept the loss but not before explanation and i dont see why it should take a qtr to find out if our drug had any effect on cd49d after all they pulled the trial did they not

IMHO the explanation has not been good enough to date i understand the drill down,
but what has come to market thus far is just not good enough

I came here as an allie gassy not a foe so please read and digest before you go off on a rant

i feel for everyone here that like myself have lost i have not moved on as yet

Enough for now

Sam

Expand

It it is something as 'simple' as the drug manufacture process was defective, then it's possibly good news.
Sure, heads must roll on who was responsible but that is a much better situation than the drug is just useless.

PER Price at posting: 0.9¢ Sentiment: Hold Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

Clarity confidence – and share price – up on bumper $203M institutional placement

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

BOE

Boss tanks -42% after quietly flagging 'potential challenges' for Honeymoon

ASX Market Close: New week sees local bourse snaps 2-day losing streak | July 28

Monday's HotCopper trends: Boss guidance, Botanix quarterly | July 28

First 9 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.9¢		Change 0.000(0.00%)		Mkt cap ! $9.786M

Open	High	Low	Value	Volume
0.9¢	0.9¢	0.9¢	$5.617K	624.0K

Buyers (Bids)

No.	Vol.	Price($)
25	6950862	0.8¢

Sellers (Offers)

Price($)	Vol.	No.
0.9¢	899422	1

View Market Depth

No.	Vol.	Price($)
25	6950862	0.008
8	3079427	0.007
2	1850000	0.006
3	1699797	0.005
1	1475000	0.004

Price($)	Vol.	No.
0.009	899422	1
0.010	8226021	8
0.011	3640661	6
0.012	2608324	4
0.013	1300000	2

Last trade - 16.10pm 28/07/2025 (20 minute delay)

PER (ASX) Chart

Ann: Becoming a substantial holder, page-9

Clarity confidence – and share price – up on bumper $203M institutional placement

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Boss tanks -42% after quietly flagging 'potential challenges' for Honeymoon

ASX Market Close: New week sees local bourse snaps 2-day losing streak | July 28

Monday's HotCopper trends: Boss guidance, Botanix quarterly | July 28

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Becoming a substantial holder, page-9

Top Stories

Clarity confidence – and share price – up on bumper $203M institutional placement

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Boss tanks -42% after quietly flagging 'potential challenges' for Honeymoon

ASX Market Close: New week sees local bourse snaps 2-day losing streak | July 28

Monday's HotCopper trends: Boss guidance, Botanix quarterly | July 28

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News